Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2021 | 443 | 1.190 |
Why?
|
| Stem Cell Niche | 3 | 2014 | 24 | 1.090 |
Why?
|
| Bone Marrow | 8 | 2018 | 418 | 1.040 |
Why?
|
| Integrin alpha6 | 2 | 2024 | 3 | 0.990 |
Why?
|
| Leukemia | 3 | 2021 | 308 | 0.850 |
Why?
|
| Meninges | 1 | 2024 | 14 | 0.840 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2017 | 330 | 0.830 |
Why?
|
| Meningeal Neoplasms | 1 | 2024 | 79 | 0.790 |
Why?
|
| Neural Pathways | 1 | 2024 | 332 | 0.730 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 316 | 0.690 |
Why?
|
| Mice, SCID | 6 | 2024 | 278 | 0.660 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 104 | 0.620 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 1089 | 0.530 |
Why?
|
| Central Nervous System | 1 | 2018 | 144 | 0.520 |
Why?
|
| Cell Movement | 5 | 2024 | 814 | 0.490 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2016 | 7 | 0.490 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 3272 | 0.480 |
Why?
|
| Stem Cell Factor | 2 | 2013 | 19 | 0.460 |
Why?
|
| Bone Marrow Cells | 2 | 2007 | 269 | 0.450 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 617 | 0.430 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2014 | 25 | 0.420 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 461 | 0.420 |
Why?
|
| Mice | 10 | 2024 | 12697 | 0.400 |
Why?
|
| Leukemia, B-Cell | 1 | 2013 | 22 | 0.390 |
Why?
|
| Blast Crisis | 1 | 2013 | 37 | 0.390 |
Why?
|
| Endothelial Cells | 2 | 2007 | 500 | 0.390 |
Why?
|
| Osteopontin | 1 | 2013 | 48 | 0.380 |
Why?
|
| Osteoblasts | 1 | 2013 | 97 | 0.380 |
Why?
|
| Animals | 16 | 2024 | 28902 | 0.370 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 110 | 0.360 |
Why?
|
| Laminin | 2 | 2024 | 89 | 0.340 |
Why?
|
| Basement Membrane | 2 | 2024 | 58 | 0.340 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 582 | 0.330 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 285 | 0.320 |
Why?
|
| Cell Communication | 2 | 2008 | 222 | 0.310 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 2888 | 0.300 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 399 | 0.290 |
Why?
|
| Interferon-alpha | 1 | 2009 | 191 | 0.290 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 177 | 0.280 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 189 | 0.280 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 77 | 0.270 |
Why?
|
| Neoplasms | 3 | 2010 | 3334 | 0.270 |
Why?
|
| Cell Cycle | 1 | 2009 | 518 | 0.260 |
Why?
|
| Stem Cells | 1 | 2010 | 395 | 0.260 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1790 | 0.260 |
Why?
|
| Stromal Cells | 1 | 2008 | 153 | 0.250 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 146 | 0.250 |
Why?
|
| Signal Transduction | 3 | 2024 | 3621 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 2 | 2018 | 174 | 0.210 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2024 | 7 | 0.210 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2024 | 16 | 0.210 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1646 | 0.200 |
Why?
|
| Benzylamines | 2 | 2016 | 17 | 0.190 |
Why?
|
| Heterocyclic Compounds | 2 | 2016 | 21 | 0.190 |
Why?
|
| Chemokine CXCL12 | 2 | 2016 | 38 | 0.190 |
Why?
|
| Humans | 16 | 2024 | 98135 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2008 | 849 | 0.180 |
Why?
|
| E-Selectin | 2 | 2016 | 31 | 0.180 |
Why?
|
| Receptors, CXCR4 | 2 | 2016 | 49 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 1028 | 0.170 |
Why?
|
| Mice, Knockout | 2 | 2024 | 2207 | 0.170 |
Why?
|
| Skull | 2 | 2018 | 280 | 0.170 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 51 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1815 | 0.160 |
Why?
|
| Macrophages | 1 | 2024 | 643 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 285 | 0.160 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 77 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2016 | 720 | 0.150 |
Why?
|
| Encephalitis | 1 | 2000 | 46 | 0.150 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 375 | 0.150 |
Why?
|
| Recurrence | 2 | 2021 | 1254 | 0.150 |
Why?
|
| Receptors, Laminin | 1 | 2018 | 5 | 0.140 |
Why?
|
| Subarachnoid Space | 1 | 2018 | 17 | 0.140 |
Why?
|
| Cerebrospinal Fluid | 1 | 2018 | 24 | 0.140 |
Why?
|
| Receptors, Vitronectin | 1 | 1998 | 5 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2013 | 419 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2000 | 3618 | 0.140 |
Why?
|
| beta-Arrestin 2 | 1 | 2017 | 5 | 0.140 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 83 | 0.140 |
Why?
|
| Heterografts | 1 | 2018 | 121 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2000 | 259 | 0.130 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 86 | 0.130 |
Why?
|
| Primary Myelofibrosis | 1 | 2017 | 72 | 0.130 |
Why?
|
| Disease Progression | 2 | 2018 | 1610 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 977 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 239 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 356 | 0.120 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 123 | 0.120 |
Why?
|
| Cytarabine | 2 | 2013 | 218 | 0.110 |
Why?
|
| Carcinoma | 1 | 1998 | 440 | 0.110 |
Why?
|
| Female | 6 | 2024 | 51570 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 246 | 0.110 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 842 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 57 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 37 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 70 | 0.100 |
Why?
|
| Protein Binding | 1 | 2016 | 1554 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 206 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1535 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 388 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 241 | 0.080 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 385 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2013 | 560 | 0.070 |
Why?
|
| Biopsy | 1 | 2013 | 1224 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 665 | 0.070 |
Why?
|
| Cell Count | 1 | 2008 | 195 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2008 | 162 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 158 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2009 | 304 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 2373 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2008 | 175 | 0.070 |
Why?
|
| Male | 5 | 2018 | 47109 | 0.060 |
Why?
|
| Adult | 4 | 2013 | 29564 | 0.060 |
Why?
|
| Apoptosis | 2 | 2017 | 1752 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2013 | 4006 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 1110 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2000 | 1416 | 0.050 |
Why?
|
| Liposomes | 2 | 2000 | 104 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2000 | 290 | 0.050 |
Why?
|
| Contrast Media | 2 | 1998 | 1011 | 0.040 |
Why?
|
| Child | 1 | 2013 | 7699 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2658 | 0.040 |
Why?
|
| Cytokines | 1 | 2005 | 889 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 1026 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 281 | 0.040 |
Why?
|
| Gadolinium | 1 | 2000 | 95 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2000 | 90 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2000 | 435 | 0.040 |
Why?
|
| Molecular Probes | 1 | 1998 | 38 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 440 | 0.030 |
Why?
|
| Rabbits | 1 | 1998 | 581 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2017 | 176 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1995 | 12 | 0.030 |
Why?
|
| Meglumine | 1 | 1995 | 36 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1995 | 142 | 0.030 |
Why?
|
| Graft Survival | 1 | 2017 | 994 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2012 | 65 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 77 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 136 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 180 | 0.020 |
Why?
|
| Liver | 1 | 1995 | 1231 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 194 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 352 | 0.020 |
Why?
|
| Kidney | 1 | 1995 | 1123 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 660 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2572 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 754 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 860 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 244 | 0.020 |
Why?
|
| Young Adult | 2 | 2013 | 7511 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 903 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 551 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1751 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1950 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2013 | 10962 | 0.020 |
Why?
|
| Aged | 2 | 2013 | 21760 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 4825 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 257 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 4116 | 0.010 |
Why?
|
| Middle Aged | 2 | 2013 | 29442 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 7387 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1995 | 118 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1995 | 219 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1995 | 201 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 1995 | 239 | 0.010 |
Why?
|
| Image Enhancement | 1 | 1995 | 503 | 0.010 |
Why?
|
| Rats | 1 | 1995 | 4072 | 0.000 |
Why?
|